Evidence map›Paper›PMID 20600451›Full record

ArticleHuman immunology2010

Identification of an alternate splice form of tapasin in human melanoma.

Alan Belicha-Villanueva, Michelle Golding, Sarah McEvoy, Nilofar Sarvaiya, Peter Cresswell, Sandra O Gollnick, Naveen Bangia

Open access · greenAbstract read
In one paragraph

Article in Human immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Alan Belicha-VillanuevaDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA.
Michelle Golding
Sarah McEvoy
Nilofar Sarvaiya
Peter Cresswell
Sandra O Gollnick
Naveen Bangia
Roswell Park Comprehensive Cancer Center · USYale University · US

Funding

StatisticsP01CA055791 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI PANDEY, RAVINDRA K. · 1992 to 2019
$36.0M
Photodynamic Therapy (PDT) Mechanisms: Tumor ImmunityR01CA098156 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GOLLNICK, SANDRA O. · 2003 to 2013
$3.6M
Regulation of Antigen Presentation by the Peptide Loading ComplexR21AI071183 · NIAID · ROSWELL PARK CANCER INSTITUTE CORP · PI BANGIA, NAVEEN · 2006 to 2007
$462k
NCI NIH HHS CA016156NCI NIH HHS CA55791NCI NIH HHS CA98156NCI NIH HHS P01 CA055791NCI NIH HHS R01 CA098156NIAID NIH HHS AI071183NIAID NIH HHS R21 AI071183
6 · The paper itself

Abstract

Assembly of major histocompatibility complex (MHC) class I molecules with peptide in the endoplasmic reticulum requires the assistance of tapasin. Alternative splicing, which is known to regulate many genes, has been reported for tapasin only in the context of mutations. Here, we report on an alternate splice form of tapasin (tpsnΔEx3) derived from a human melanoma cell line that does not appear to be caused by mutations. Excision of exon 3 results in deletion of amino acids 70 to 156 within the beta barrel region, but the membrane proximal Ig domain, the transmembrane domain, and cytoplasmic tail of tapasin are intact. Introduction of tpsnΔEx3 into a tapasin-deficient cell line does not restore MHC class I expression at the cell surface. Similar to a previously described tapasin mutant (tpsnΔN50), tpsnΔEx3 interacts with TAP. Therefore, we used these altered forms of tapasin to test the importance of MHC class I interaction with TAP. In the presence of wild-type tapasin, transfection of tpsnΔN50, but not tpsnΔEx3, reduced MHC class I expression at the cell surface likely due its ability to compete MHC class I molecules from TAP. Together these findings suggest that tumor cells may contain alternate splice forms of tapasin which may regulate MHC class I antigen presentation.

Indexed as

Alternative SplicingAntigen PresentationATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 2Cell Line, TumorHistocompatibility Antigens Class IHumansMelanomaMembrane Transport ProteinsMultiprotein ComplexesProtein BindingProtein IsoformsProtein Structure, TertiarySequence DeletionTransgenesATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 2Histocompatibility Antigens Class IMembrane Transport ProteinsMultiprotein ComplexesProtein IsoformsTAP1 protein, humantapasin

Identifiers

PMID20600451
PMCPMC2952442
OpenAlexW2015605211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.